R. Camisasca

1.7k total citations
13 papers, 1.2k citations indexed

About

R. Camisasca is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, R. Camisasca has authored 13 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 6 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in R. Camisasca's work include Diabetes Treatment and Management (4 papers), Diabetes Management and Research (4 papers) and Metabolism, Diabetes, and Cancer (3 papers). R. Camisasca is often cited by papers focused on Diabetes Treatment and Management (4 papers), Diabetes Management and Research (4 papers) and Metabolism, Diabetes, and Cancer (3 papers). R. Camisasca collaborates with scholars based in Italy, Switzerland and United States. R. Camisasca's co-authors include Erika Rochotte, Emanuele Bosi, Alan J. Garber, A. Couturier, Michelle A. Baron, Sujata Vaidyanathan, Floriane Cressier, S. Dejager, Julio Rosenstock and Michel Azizi and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Journal of the American Society of Nephrology.

In The Last Decade

R. Camisasca

13 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Camisasca Italy	10	1.0k	380	369	300	233	13	1.2k
Samuel S. Engel United States	5	1.7k 1.7×	654 1.7×	549 1.5×	430 1.4×	276 1.2×	6	1.9k
H.J. Woerle Germany	18	1.6k 1.6×	745 2.0×	701 1.9×	126 0.4×	281 1.2×	31	1.7k
Lisa E. Porter United States	8	1.1k 1.1×	570 1.5×	353 1.0×	278 0.9×	58 0.2×	10	1.5k
Toshihiko Shiraiwa Japan	18	733 0.7×	358 0.9×	461 1.2×	186 0.6×	146 0.6×	57	1.2k
Maria Gerasimova United States	9	974 0.9×	528 1.4×	600 1.6×	89 0.3×	130 0.6×	12	1.4k
Markus Alter Germany	15	458 0.4×	217 0.6×	157 0.4×	194 0.6×	208 0.9×	23	862
Mark Warren United States	14	1.8k 1.8×	745 2.0×	643 1.7×	192 0.6×	104 0.4×	32	2.0k
Elsie Allen United States	13	1.7k 1.7×	641 1.7×	682 1.8×	82 0.3×	157 0.7×	20	2.1k
Ivan Tkáč Slovakia	19	580 0.6×	332 0.9×	382 1.0×	158 0.5×	109 0.5×	71	1.0k
Michelle A. Baron United States	18	1.8k 1.8×	748 2.0×	777 2.1×	62 0.2×	403 1.7×	27	2.0k

Countries citing papers authored by R. Camisasca

Since Specialization

Citations

This map shows the geographic impact of R. Camisasca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Camisasca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Camisasca more than expected).

Fields of papers citing papers by R. Camisasca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Camisasca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Camisasca. The network helps show where R. Camisasca may publish in the future.

Co-authorship network of co-authors of R. Camisasca

This figure shows the co-authorship network connecting the top 25 collaborators of R. Camisasca. A scholar is included among the top collaborators of R. Camisasca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Camisasca. R. Camisasca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Prato, Stefano Del, R. Camisasca, Candy Wilson, & P. Fleck. (2014). Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study. Diabetes Obesity and Metabolism. 16(12). 1239–1246. 64 indexed citations

Garber, A. J., James E. Foley, Mary Ann Banerji, et al.. (2008). Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*. Diabetes Obesity and Metabolism. 10(11). 1047–1056. 194 indexed citations

Rosenstock, Julio, Michelle A. Baron, R. Camisasca, et al.. (2007). Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 9(2). 175–185. 222 indexed citations

Bosi, Emanuele, et al.. (2007). Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Diabetes Care. 30(4). 890–895. 374 indexed citations

Vaidyanathan, Sujata, et al.. (2006). Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. British Journal of Clinical Pharmacology. 62(6). 690–698. 58 indexed citations

Monti, Lucilla D., Emanuela Setola, Gabriele Fragasso, et al.. (2005). Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. American Journal of Physiology-Endocrinology and Metabolism. 290(1). E54–E59. 52 indexed citations

Vaidyanathan, Sujata, et al.. (2005). Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. American Journal of Hypertension. 18(5). A75–A76. 7 indexed citations

Azizi, Michel, Joël Ménard, Alvine Bissery, et al.. (2004). Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption. Journal of the American Society of Nephrology. 15(12). 3126–3133. 191 indexed citations

Flesch, Gérard, et al.. (2003). Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 41(7). 299–308. 13 indexed citations

10.

Pontiroli, Antonio E. & R. Camisasca. (2002). Additive effect of overweight and type 2 diabetes in the appearance of coronary heart disease but not of stroke: a cross-sectional study. Acta Diabetologica. 39(2). 83–90. 5 indexed citations

11.

Caminiti, Maurizio, et al.. (2000). Association of Obesity and Type II Diabetes Mellitus as a Risk Factor for Gallstones. Digestive Diseases and Sciences. 45(10). 2002–2006. 41 indexed citations

12.

Pontiroli, Antonio E., et al.. (1998). Markers of insulin resistance are associated with cardiovascular morbidity and predict overall mortality in long-standing non-insulin-dependent diabetes mellitus. Acta Diabetologica. 35(1). 52–56. 12 indexed citations

13.

Pontiroli, Antonio E., et al.. (1996). Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.. The Journal of Clinical Endocrinology & Metabolism. 81(10). 3727–3732. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact